Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Characterization of TCP-1 probes for molecular imaging of colon cancer.

Liu Z, Gray BD, Barber C, Bernas M, Cai M, Furenlid LR, Rouse A, Patel C, Banerjee B, Liang R, Gmitro AF, Witte MH, Pak KY, Woolfenden JM.

J Control Release. 2016 Oct 10;239:223-30. doi: 10.1016/j.jconrel.2016.08.033. Epub 2016 Aug 26.

PMID:
27574992
2.

Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Tsaitas C, Semertzidou A, Sinakos E.

World J Hepatol. 2014 Apr 27;6(4):178-87. doi: 10.4254/wjh.v6.i4.178. Review.

3.

Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies.

Monstad I, Hovde O, Solberg IC, A Moum B.

Ann Gastroenterol. 2014;27(2):95-104. Review.

4.

Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Dyson JK, Rutter MD.

World J Gastroenterol. 2012 Aug 7;18(29):3839-48. doi: 10.3748/wjg.v18.i29.3839. Review.

5.

Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new?

Guagnozzi D, Lucendo AJ.

World J Gastrointest Endosc. 2012 Apr 16;4(4):108-16. doi: 10.4253/wjge.v4.i4.108.

6.

Current management of inflammatory bowel disease and colorectal cancer.

Mattar MC, Lough D, Pishvaian MJ, Charabaty A.

Gastrointest Cancer Res. 2011 Mar;4(2):53-61.

7.

Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor.

Jokerst JV, Miao Z, Zavaleta C, Cheng Z, Gambhir SS.

Small. 2011 Mar 7;7(5):625-33. doi: 10.1002/smll.201002291. Epub 2011 Feb 8.

8.

Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies.

Lakatos PL, Lakatos L.

World J Gastroenterol. 2008 Jul 7;14(25):3937-47. Review.

9.

Techniques for targeting screening in ulcerative colitis.

Hurlstone DP, Brown S.

Postgrad Med J. 2007 Jul;83(981):451-60. Review.

Supplemental Content

Support Center